Grifols, S.A.

NasdaqGS:GRFS 株式レポート

時価総額：US$6.8b

Grifols マネジメント

マネジメント 基準チェック /34

Grifolsの CEO はNacho Abia Buenacheで、 Apr2024年に任命され、 の在任期間は 2.08年です。 の年間総報酬は€ 3.52Mで、 56.9%給与と43.1%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.019%を直接所有しており、その価値は$ 1.28M 。経営陣と取締役会の平均在任期間はそれぞれ7.3年と7年です。

主要情報

Nacho Abia Buenache

最高経営責任者

€3.5m

報酬総額

CEO給与比率56.87%
CEO在任期間2.1yrs
CEOの所有権0.02%
経営陣の平均在職期間7.3yrs
取締役会の平均在任期間7yrs

経営陣の近況

Recent updates

Seeking Alpha • Dec 08

Grifols: Positive/Neutral Scenario Posits An Upside

Summary Grifols, S.A. has executed a turnaround, with Q3 '25 results confirming improved fundamentals, reduced leverage, and restored dividend, supporting a renewed 'Buy' rating. GRFS now trades at a normalized P/E of 14-15x, but forward multiples drop below 9x, offering significant upside if growth forecasts materialize. Operational improvements include 7%+ revenue growth, double-digit EBITDA gains, positive FCF, and leverage below 4.3x, with further refinancing underway. My GRFS share price target reflects double-digit annualized upside potential, underpinned by forecasted EPS growth and multiple expansion, despite lingering competitive and leverage risks. Read the full article on Seeking Alpha
Seeking Alpha • Apr 23

Grifols: A Market Setback Turns Into Buying Opportunity

Summary Grifols, a Spanish multinational specializing in plasma-derived therapies, is undervalued due to historical mismanagement but holds a strong market position with significant competitive advantages. New management has implemented an operational improvement plan, showing positive results in 2024, including record revenues, improved EBITDA margins, and increased free cash flow. Key risks include potential U.S. immigration policies affecting plasma supply and the emergence of recombinant protein substitutes, which could erode revenue by 2028. The business is poised for growth with a strategic plan targeting revenue growth, improved margins, and significant free cash flow generation, making it an attractive investment opportunity. Read the full article on Seeking Alpha
Seeking Alpha • Feb 27

Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale

Summary Grifols remains a strong long-term investment due to its leading position in the plasma industry and improving financial fundamentals, despite short-term volatility and lack of a dividend. The company's revenue and EBITDA growth, improved leverage ratio, and significant liquidity highlight its resilience and potential for future profitability. Grifols' valuation is attractive, with a potential upside to €20/share, driven by EPS growth and market expansion in plasma-derived products. I maintain a "BUY" rating for Grifols, expecting a significant return on investment over the next 1-4 years. Read the full article on Seeking Alpha
Seeking Alpha • Nov 29

Grifols: More Attractive Than In A Very Long Time

Summary I don't divest unless the fundamental thesis changes; Grifols' buyout offer from Brookfield Asset Management is undervalued, so I maintain my "Buy" stance. Despite Brookfield's offer, I believe Grifols is worth more, as supported by recent 3Q24 results and the transaction committee's recommendation. The transaction committee advises against accepting the €10.5/share offer, aligning with my view that Grifols' real value is higher. This situation is instructive for valuation investors, demonstrating the importance of assessing a company's true worth beyond buyout offers. Read the full article on Seeking Alpha
Seeking Alpha • Oct 03

Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down

Summary Grifols, S.A. is undervalued and worth more than its current market valuation, making it a strong buy even without a potential Brookfield buyout. The company leads the global plasma market, with significant growth in immunoglobulin and albumin segments, and has a robust infrastructure and geographical reach. Despite facing competition and emerging technologies, Grifols' fundamentals are solid, with impressive 2024 earnings forecasts and improving margins and leverage. The lack of a dividend is a downside, but the potential for significant returns based on historical P/E ratios makes Grifols a speculative “Buy”. Read the full article on Seeking Alpha
Seeking Alpha • Jul 16

Grifols: Stay On The Sidelines

Summary Grifols leverage and governance concerns are primarily addressed. The company confirms discussions around a potential combined PE/family bid offer. Still, there is a high debt and negligible FCF generation to consider. We remain neutral. Read the full article on Seeking Alpha
Seeking Alpha • May 07

Grifols: Why To Watch From The Sidelines

Summary Grifols, a major player in global plasma extraction and processing, has experienced a significant 43% decline in stock price in 2024 following a bearish report from Gotham. KPMG and the Spanish regulator have offered a more favorable perspective based on Grifols’ 2023 results, suggesting that while the company’s structure warrants caution, it is not without value. For investors seeking value, the question is: Is there enough margin of safety? A closer examination reveals that Grifols is facing several challenges compared to its competitors, compounded by debt. Read the full article on Seeking Alpha
Seeking Alpha • Mar 05

Grifols: Q4 Was Positive, Still Too Many Question Marks

Summary Grifols faces new accusations from the hedge fund Gotham City. Gotham City questions loans and outgoing flows recorded in Grifols' financial report, as well as the role of Scranton Enterprises. Grifols disclosed a lack of FCF generation in 2024. We are neutral, given a soft outlook for the current year. On a positive note, Grifols confirmed the Shanghai RAAS equity stake divestment. Read the full article on Seeking Alpha
Seeking Alpha • Jan 10

Grifols: I've Read The Short-Seller Report, And I Mostly Disagree

Summary Grifols' position in the pharma industry has dropped due to a short-seller report, causing its stock to decline. The report questions the accounting treatment of M&As and consolidation of entities in Grifols' filings. I believe that the allegations in the report are not significant enough to warrant a 20% drop in the company's stock and plans to wait for a reaction before adding more to their stake. Read the full article on Seeking Alpha

CEO報酬分析

Grifols の収益と比較して、Nacho Abia Buenache の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2026n/an/a

€415m

Dec 31 2025€4m€2m

€402m

報酬と市場: Nachoの 総報酬 ($USD 4.09M ) は、 US市場 ($USD 8.38M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Nachoの報酬と会社の業績を比較するにはデータが不十分です。

CEO

Nacho Abia Buenache (57 yo)

2.1yrs
在職期間
€3,517,000
報酬

Mr. Jose Ignacio Abia Buenache, also known as Nacho, serves as Chief Executive Officer of Grifols, S.A. from April 1, 2024 and has been its Director since February 26, 2024. Mr. Abia Buenache had been Chie...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Jose Ignacio Abia Buenache
CEO & Director2.1yrs€3.52m0.019%
$ 1.3m
Rahul Srinivasan
Chief Financial Officer1.7yrsデータなし0.0015%
$ 102.7k
Lluis Gomez
Senior Vice President of Strategy & COO Officeno dataデータなしデータなし
Daniel Segarra
Head of Investor Relations & Sustainability and Vice Presidentno dataデータなしデータなし
David Bell
Chief Corporate Affairs & Legal Officer23.3yrsデータなし0.0029%
$ 200.0k
Enrique de la Torre
Chief Compliance Officer7.3yrsデータなしデータなし
Montse Ribas
Chief Communications and Reputation Officer1.2yrsデータなしデータなし
Camille Alpi
Chief Human Resources & Talent Officer2.3yrsデータなしデータなし
Vicente Blanquer Torre
Chief Quality Officer33.3yrsデータなしデータなし
Sergio Adell
President of Commercial Tech Support7.3yrsデータなしデータなし
Daniel Coit
Chief Industrial Services Officer7.3yrsデータなしデータなし
Luis Garçon
Managing Director Laboratorios Grifols7.8yrsデータなしデータなし
7.3yrs
平均在職期間
53yo
平均年齢

経験豊富な経営陣: GRFSの経営陣は経験豊富で経験豊富です（平均在職期間は7.3年）。

取締役

名称ポジション在職期間報酬所有権
Jose Ignacio Abia Buenache
CEO & Director2.3yrs€3.52m0.019%
$ 1.3m
Iñigo Mardones
Independent Director11yrs€164.00kデータなし
Victor Grifols Roura
Chairman of Honourno data€129.00kデータなし
Juan Twose Roura
Member of the Advisory Committee11.3yrs€380.00kデータなし
Raimon Grifols Roura
Vice-Chairman11yrs€129.00k0.033%
$ 2.2m
Tomas Daga Gelabert
Independent External Director26.1yrs€129.00k0.044%
$ 3.0m
Víctor Grifols Deu
Proprietary Director10yrs€4.45m0.016%
$ 1.1m
Albert Coma-Cros
Proprietary Director2.4yrs€129.00kデータなし
Enriqueta Font
Independent Director7yrs€139.00kデータなし
Montserrat Abellana
Independent Director3.9yrs€164.00kデータなし
Susana Gonzalez Rodriguez
Independent Director3.9yrs€154.00kデータなし
Anne-Catherine Berner
Independent Chairman1.9yrs€380.00kデータなし
7.0yrs
平均在職期間
61yo
平均年齢

経験豊富なボード: GRFSの 取締役会 は 経験豊富 であると考えられます ( 7年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/26 03:17
終値2026/05/26 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Grifols, S.A. 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。32

アナリスト機関
null nullBanco de Sabadell. S.A.
Luis ArredondoBanco de Sabadell. S.A.
Jaime EscribanoBanco Santander